Expertise in
2
conditions

Isabelle Fajac

Paris, FR 
Expertise in
2
conditions
Paris, FR 

Overview

Isabelle Fajac practices practicing medicine in Paris, France.

Ms. Fajac is highly rated in 2 conditions, according to our data. Her clinical expertise encompasses Cystic Fibrosis, Exocrine Pancreatic Insufficiency, Pseudomonas Stutzeri Infections, Acrokeratoelastoidosis of Costa, and Lung Transplant.

She is actively involved in clinical research, co-authoring 64 peer reviewed articles and participating in 3 clinical trials.

Gender

Female

Locations

Paris, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified
Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified
Enrollment Status: Completed
Publish Date: April 10, 2025
Intervention Type: Drug
Study Phase: Not Applicable
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis
Enrollment Status: Completed
Publish Date: January 18, 2023
Intervention Type: Drug, Other
Study Drug: Lenabasum
Study Phase: Phase 2
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once-Daily for 48 Weeks in Adult Patients With Cystic Fibrosis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once-Daily for 48 Weeks in Adult Patients With Cystic Fibrosis
Enrollment Status: Completed
Publish Date: September 04, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 2 Less Clinical Trials

64 Total Publications

Persistence of static lung hyperinflation in adults with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor.
Persistence of static lung hyperinflation in adults with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor.
Journal: Thorax
Published: March 30, 2026

Frequently Asked Questions about Isabelle Fajac

Is Isabelle Fajac a top-rated expert for Cystic Fibrosis?

MediFind is an objective health platform that identifies experts based on real-world data. Isabelle Fajac is classified as an Elite expert for Cystic Fibrosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Isabelle Fajac participate in research or clinical trials?

Yes. Isabelle Fajac has published 64 articles and abstracts on conditions like Cystic Fibrosis. You can view a list of Isabelle Fajac's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Fajac's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile